Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
362 participants
INTERVENTIONAL
2022-09-08
2022-10-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Is the investigational device accurate and reliable at detecting cannabis impairment?
* is the device safe for the collection of eye movement data from cannabis intoxicated individuals? Participants will be administered a series of Drug Recognition Expert Ocular Tests via the Gaize headset following cannabis consumption.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Eye Tracking as a Biomarker of Cannabis Effects
NCT04100590
Detection of Cannabis Impairment With an Eye Tracker
NCT03813602
Detection of Cannabis Impairment With ISBRG's SpotLight-THC
NCT05276232
Differences in Cannabis Impairment and Its Measurement Due to Route of Administration
NCT03122691
Cannabis Impairment Detection Application (CIDA)
NCT04230460
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gaize Device
Cannabis Impairment Test
Automated Drug Recognition Expert Ocular Tests administered via VR Headset, includes test for Lack of Smooth Pursuit, Horizontal and Vertical Gaze Nystagmus, Lack of Convergence, and Pupillary Rebound Dilation. Tests are preceded by an automated system calibration process.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cannabis Impairment Test
Automated Drug Recognition Expert Ocular Tests administered via VR Headset, includes test for Lack of Smooth Pursuit, Horizontal and Vertical Gaze Nystagmus, Lack of Convergence, and Pupillary Rebound Dilation. Tests are preceded by an automated system calibration process.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Having used cannabis at least one time prior
* Having access to legal cannabis
* Normal or corrected to normal vision using either glasses or contact lenses, or surgery.
Exclusion Criteria
* Having a prosthetic eye
* Blood pressure greater than 160/90 mmHg and heart rate greater than 100 bpm.
19 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dicentra Inc.
INDUSTRY
Gaize
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ken Fichtler
Role: STUDY_CHAIR
Gaize
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dicentra
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22-GPHCV-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.